1 March 2024 - Launched in January 2024, IRP aims to further help bring life-saving new medicines to UK patients without delay.

A new formulation for Xgeva (denosumab), a treatment used in adults to prevent serious bone-related complications caused by bone metastasis and to treat giant cell tumour of bone in adults and adolescents, is the first product to be authorised by the MHRA via the new International Recognition Procedure (IRP).

Read UK Government press release